IMRX Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Immuneering Corp.'s net margin of 20.1%. Immuneering Corp.'s return on equity of -78.54% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.

Immuneering Corp. has a consensus price target of $16.83, signalling upside risk potential of 150.12%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 22.8%. Given that Immuneering Corp. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Immuneering Corp. is more attractive than Alnylam Pharmaceuticals, Inc..

Immuneering Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.

Immuneering Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering Corp. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Immuneering Corp. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Immuneering Corp.'s net income of -$15M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Immuneering Corp.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,665.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering Corp. is 323.21x versus 16.43x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BridgeBio Pharma, Inc. has a net margin of -- compared to Immuneering Corp.'s net margin of -153.22%. Immuneering Corp.'s return on equity of -78.54% beat BridgeBio Pharma, Inc.'s return on equity of --.

Immuneering Corp. has a consensus price target of $16.83, signalling upside risk potential of 150.12%. On the other hand BridgeBio Pharma, Inc. has an analysts' consensus of $86.56 which suggests that it could grow by 14.19%. Given that Immuneering Corp. has higher upside potential than BridgeBio Pharma, Inc., analysts believe Immuneering Corp. is more attractive than BridgeBio Pharma, Inc..

Immuneering Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BridgeBio Pharma, Inc. has a beta of 1.256, suggesting its more volatile than the S&P 500 by 25.58%.

Immuneering Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering Corp. pays -- of its earnings as a dividend. BridgeBio Pharma, Inc. pays out -- of its earnings as a dividend.

Immuneering Corp. quarterly revenues are --, which are smaller than BridgeBio Pharma, Inc. quarterly revenues of $120.7M. Immuneering Corp.'s net income of -$15M is higher than BridgeBio Pharma, Inc.'s net income of -$184.9M. Notably, Immuneering Corp.'s price-to-earnings ratio is -- while BridgeBio Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering Corp. is 323.21x versus 40.81x for BridgeBio Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech, Inc. has a net margin of -- compared to Immuneering Corp.'s net margin of 50.07%. Immuneering Corp.'s return on equity of -78.54% beat Fortress Biotech, Inc.'s return on equity of -223.06%.

Immuneering Corp. has a consensus price target of $16.83, signalling upside risk potential of 150.12%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 187.43%. Given that Fortress Biotech, Inc. has higher upside potential than Immuneering Corp., analysts believe Fortress Biotech, Inc. is more attractive than Immuneering Corp..

Immuneering Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.490, suggesting its more volatile than the S&P 500 by 49.031%.

Immuneering Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering Corp. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Immuneering Corp. quarterly revenues are --, which are smaller than Fortress Biotech, Inc. quarterly revenues of $17.6M. Immuneering Corp.'s net income of -$15M is lower than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Immuneering Corp.'s price-to-earnings ratio is -- while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering Corp. is 323.21x versus 1.76x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Immuneering Corp.'s net margin of 38.89%. Immuneering Corp.'s return on equity of -78.54% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Immuneering Corp. has a consensus price target of $16.83, signalling upside risk potential of 150.12%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $795.38 which suggests that it could grow by 1.33%. Given that Immuneering Corp. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Immuneering Corp. is more attractive than Regeneron Pharmaceuticals, Inc..

Immuneering Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Immuneering Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Immuneering Corp. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Immuneering Corp. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Immuneering Corp.'s net income of -$15M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Immuneering Corp.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering Corp. is 323.21x versus 6.07x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.